PMEA polymer-coated PVC tubing maintains anti-thrombogenic properties during in vitro whole blood circulation.
Poly(2-methoxyethylacrylate) (PMEA) is a new coating material that appears to reduce protein and platelet adsorption. However, the exact performance of PMEA coated circuit remains to be revealed in well-controlled experiments. Therefore, we compared its hemocompatibility with covalent-bound heparin-, and non-coated circuits during 6 hours of in vitro circulation, using donor blood from six volunteers. In our model, simple tubing circuits containing one-way ball valve were placed on the rotary table, which moved alternatively to generate pulsatile recirculation of heparinized human blood inside the tubing. Using this model, we expected fine assessment of the material surface, because we could reduce blood damage by avoiding air and a blood pump. Moreover, the small capacity of circuit allowed us to compare three kinds of circuits using a single unit of donor blood, eliminating effects by possible variations between blood donors. The anti-thrombin capacity of the PMEA-coated circuits was maintained even after six hours blood circulation, whereas surface thrombin generation increased markedly after use in non-coated circuits (P<0.05). Deposition of fibrin onto PMEA circuits was reduced more than 30% compared with heparin and non-coated circuits (P<0.05). However, the increase of plasma Factor XIIa was similar in all circuits. Increase of CD11b expression on circulating leukocytes and of plasma C3a was ameliorated in the heparin- and PMEA-coated circuits (P<0.05). PMEA-coated circuits appear to maintain their anti-thrombogenicity during use, otherwise PMEA-coated and heparin-coated circuits showed a similar character in hemocompatibility. This long-standing anti-thrombogenicity might be attributable to less adsorption of activated blood components onto the surface.
Yoshizaki
T
T
Department of Cardio-Thoracic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
Tabuchi
N
N
van Oeveren
W
W
Shibamiya
A
A
Koyama
T
T
Sunamori
M
M
D000179:Acrylates; D000925:Anticoagulants / Q000494:pharmacology; D000991:Antithrombins; D020099:Coated Materials, Biocompatible; D005112:Extracorporeal Circulation / Q000295:instrumentation*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008422:Materials Testing; D008955:Models, Cardiovascular; D011108:Polymers; D011143:Polyvinyl Chloride
D000179:Acrylates; D000925:Anticoagulants; D000991:Antithrombins; D020099:Coated Materials, Biocompatible; D011108:Polymers; C413485:poly(2-methoxyethylacrylate); D011143:Polyvinyl Chloride; D006493:Heparin